Status Epilepticus Market

Global Status Epilepticus Market Size (2023 to 2028)

The global status epilepticus market is expected to grow from USD 2 billion in 2023 to USD 2.56 billion by 2028, growing at a CAGR of 5.11% from 2023 to 2028. 

Market Drivers:

The growing prevalence of neurological disorders is one of the major factors propelling the status epilepticus market. The prevalence of neurological disorders is high among adults and as the global population continues to age, the number of people suffering from neurological disorders grows, including status epilepticus. Factors such as stress, poor diet, and sedentary behavior contribute to the development of exacerbation of neurological disorders and can increase the risk of status epilepticus in susceptible individuals.

The growing prevalence of epilepsy due to rising incidences of several birth-related injuries contributes to the growth of the status epilepticus market. The incidence of complications such as such as oxygen deprivation and trauma during delivery during child birth has seen a spike in the recent past. These complications affect the baby’s brain and can lead to neurological damage and this damage increases the risk of epilepsy. The hypoxic-ischemic encephalopathy condition occurs when the brain is deprived of oxygen and blood flow, often due to complications during birth. This can result in brain damage, including status epilepticus in affected infants.

Technological advancements in diagnostic technologies for accurate detection, rising awareness about the significance of prompt treatment, increasing research in neuroscience and neurology and growing demand for efficient seizure management solutions drive status epilepticus market growth. The development of novel antiepileptic drugs and therapies, rapid adoption of personalized treatment approaches, growing emphasis on improving patient outcomes and quality of life, and increasing number of initiatives from the governments of several countries supporting epilepsy awareness and care further fuel the market’s growth rate.

Technological innovations in seizure detection and monitoring devices, a growing geriatric population prone to neurological disorders, rising emphasis on early intervention to prevent status epilepticus, a surge in demand for emergency medical services for seizures and an increasing number of clinical trials for innovative epilepsy management solutions further contribute to the growth of the status epilepticus market.

MARKET RESTRAINTS:

Limited awareness and understanding of status epilepticus among healthcare professionals and the public, challenges in accurate and timely diagnosis due to varying clinical presentations and misdiagnosis and limited availability of specialized medical centers and resources for managing status epilepticus cases hamper the market growth. Lack of standardized treatment protocols and guidelines, potential adverse effects of antiepileptic medications and concerns about their long-term safety and high economic burden on patients and healthcare systems for intensive care and treatment impedes the market growth. Stigma and misconceptions associated with epilepsy affecting patient and family well-being, limited research and funding for status epilepticus, difficulty in predicting and preventing status epilepticus occurrences and inadequate public health campaigns addressing epilepsy awareness and the importance of early intervention hinder the market growth.

Impact of COVID-19 on the global status epilepticus market:

The COVID-19 pandemic crisis has steadily impacted the global status epilepticus market. There was a large strain on the healthcare system due to the widespread novel coronavirus and resulted in the postponement of non-urgent medical procedures and delayed diagnosis and treatment of status epilepticus cases. The measures taken by the governments of several countries, such as social isolation, strict restrictions and lockdowns, resulted in a significant disruption in the global supply chains and hampered the production, distribution, and transportation of drugs and the availability of medical devices used to treat status epilepticus. Many clinical trials and research initiatives unrelated to the COVID-19 pandemic faced delays. This could have impacted the development of new treatments, medication, and technologies for status epilepticus. All these factors have shown an unfavorable impact on the status epilepticus market and hampered the market growth during the COVID-19 pandemic. However, the market has entered the recovery phase and is anticipated to witness a healthy CAGR during the forecast period.

REPORT COVERAGE:

This research report on the status epilepticus market has been segmented and sub-segmented based on the type, drug type, distribution channel and region.

Status Epilepticus Market – By Type:

• Conclusive Epilepticus
• Non-Conclusive Epilepticus

Based on type, the conclusive epilepticus segment is expected to account for the major share of the global market during the forecast period. Conclusive epileptic is a diagnosis based on clinical and diagnostic criteria. Advancements in medical imaging, the growing awareness among healthcare professionals, rising need for more accurate and timely diagnosis for targeted treatment for conclusive cases and the advancement in personalized medicine, including genetic and biomarker-based approaches, majorly drive the growth of the conclusive epilepticus segment in the global market.

The non-conclusive epilepticus segment is anticipated to hold a considerable share of the global market during the forecast period.

Status Epilepticus Market – By Drug Type:

• Ganaxolone
• Diazepam
• Fosphenytoin 
• Valproate 
• Phenobarbital
• Phenytoin
• Others

Based on drug type, the phenobarbital drug segment is anticipated to hold a substantial share of the global status epilepticus market during the forecast period. Phenobarbital drugs are commonly used for the treatment of status epilepticus and has well-established efficacy and familiarity among healthcare professionals. Phenobarbital drugs are also used in emergency to rapidly control seizures and prevent the progression of status epilepticus.

On the other hand, the ganaxolone segment is anticipated to account for a considerable share of the global market during the forecast period.

Status Epilepticus Market – By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Based on distribution channels, the retail pharmacies segment is expected to lead the market during the forecast period owing to the preference of the people towards retail pharmacies.

The online pharmacies segment is anticipated to grow at the highest CAGR in the coming years. In the recent years, people rapidly adopt digital health services such as telehealth and telemedicine due to the COVID-19 pandemic. Considering the ease of convenience and time-saving ability have increased the digital channels use for the healthcare needs among patients.

Status Epilepticus Market – By Region:

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

North America is predicted to hold the largest share of the global status epilepticus market during the forecast period. North America has well-developed healthcare and advanced healthcare infrastructure, this support accurate diagnosis, timely intervention, and comprehensive management of status epilepticus cases. North America also has a high prevalence of neurological disorders and this drives the demand for effective treatment and intervention and stimulates the regional market growth. The growing number of R&D activities in the pharmaceutical and biotechnology industries, an increasing number of clinical trials and research studies focused on status epilepticus and strong regulatory framework further propel the North American market growth.

Europe was the second-largest regional market in 2022 and is expected to grow at a healthy CAGR during the forecast period. The presence of a well-advanced healthcare systems, including well-equipped medical facilities, specialized neurology centers and trained healthcare personnel is one of the major factors driving the growth of the European market. Factors such as well-defined reimbursement systems that enhance patient access to therapies and increasing number of initiatives such as European Epilepsy Day and neurology research grants further contribute to the European market growth.

The Asia-Pacific region is expected to showcase highest CAGR in the worldwide market among all the regions during the forecast period. The growing number of improvements in the healthcare infrastructure, increasing patient awareness, and emerging research initiatives primarily drive the growth of the APAC market growth. The rising prevalence of epilepsy in densely populated regions, increasing investments in neurology research and epilepsy treatment, rapid adoption of telemedicine to reach remote areas for epilepsy care and growing support from epilepsy advocacy groups for awareness campaigns further fuel the growth rate of the Latin American market.

The Latin America is expected to grow at a healthy CAGR during the forecast period. The Middle East and Africa region is anticipated to hold a moderate share of the global market in the coming years.

KEY MARKET PLAYERS:

SAGE Therapeutics, Marinus Pharmaceuticals, H.Lundbeck, CURx Pharmaceuticals, Sunovion Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Inc., Sanofi S.A., GlaxoSmithKline Plc, and Johnson & Johnson are some of the major companies in the global market.